<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01873365</url>
  </required_header>
  <id_info>
    <org_study_id>200089</org_study_id>
    <nct_id>NCT01873365</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Burden of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged Sixty Years and Above</brief_title>
  <official_title>Physician-practice Based Cohort Study to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The study aims to estimate the incidence of herpes zoster (HZ), proportion of postherpetic
      neuralgia (PHN) and the economic burden and impact on quality of life, in Japanese adults
      greater than or equal to sixty years of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of HZ cases reported in the study area, overall and within a specific age-group and gender. The following age-groups will be considered: 60-69, 70-79 and ≥ 80 years of age.</measure>
    <time_frame>Approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of HZ-associated PHN pain, persisting between 90 and 270 days after the initial visit for this study.</measure>
    <time_frame>Day 90 - Day 270</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of HZ-associated hospitalisations.</measure>
    <time_frame>Day 0 - Day 270</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of HZ-associated any pain, persisting between 0 and 270 days after the initial visit for this study.</measure>
    <time_frame>Day 0 - Day 270</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anamnestic information, clinical parameters and complications related to HZ.</measure>
    <time_frame>Day 0 - Day 270</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct medical, direct non-medical and indirect costs related to HZ.</measure>
    <time_frame>Day 0 - Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) assessment in HZ subjects.</measure>
    <time_frame>Day 0 - Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct medical, direct non-medical and indirect costs related to PHN.</measure>
    <time_frame>Day 90 - Day 270</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL assessment in PHN subjects.</measure>
    <time_frame>Day 90 - Day 270</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the following factors on the development of PHN: - age, - gender, - concomitant disease, - current immunosuppressive therapy, - HZ severity at first consultation, - timing of initiation of treatment with antiviral agent etc.</measure>
    <time_frame>Day 0 - Day 270</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">448</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>Prospective Group</arm_group_label>
    <description>Japanese adults, aged greater than or equal to sixty years, diagnosed with HZ.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>Case report forms (CRFs), logbooks and booklets.</description>
    <arm_group_label>Prospective Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Japanese adults, male or female, greater than or equal to sixty years of age, presenting
        with HZ at the participating sites.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who, in the opinion of the investigator, can and will comply with the
             requirements of the protocol.

          -  Written informed consent obtained from the subject.

          -  A male or female greater than or equal to sixty years of age, presenting with HZ at
             the time of enrollment.

          -  HZ diagnosis.

               -  Is the subject's first outpatient diagnosis for this HZ episode. OR

               -  Took place up to seven days prior to the initial visit for the present study.
                  Note: Recurrent HZ cases may be enrolled as new cases based on the investigator's
                  clinical practice.

        Exclusion Criteria:

        • Not applicable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>084-0906</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>084-0909</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>084-0912</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>085-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>085-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>085-0036</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>085-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>085-0057</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>085-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>085-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>085-0805</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>085-0813</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>085-0822</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>085-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2013</study_first_submitted>
  <study_first_submitted_qc>June 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2013</study_first_posted>
  <last_update_submitted>January 16, 2017</last_update_submitted>
  <last_update_submitted_qc>January 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of life</keyword>
  <keyword>Herpes zoster</keyword>
  <keyword>Postherpetic neuralgia</keyword>
  <keyword>Japan</keyword>
  <keyword>Physician-practice</keyword>
  <keyword>Adults</keyword>
  <keyword>Health economics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

